


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:50:54Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12407133" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12407133</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>kidney360</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="editorial" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Kidney360</journal-id><journal-id journal-id-type="iso-abbrev">Kidney360</journal-id><journal-id journal-id-type="pmc-domain-id">4060</journal-id><journal-id journal-id-type="pmc-domain">kidney360</journal-id><journal-id journal-id-type="publisher-id">Kidney360</journal-id><journal-title-group><journal-title>Kidney360</journal-title></journal-title-group><issn pub-type="epub">2641-7650</issn><publisher><publisher-name>American Society of Nephrology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12407133</article-id><article-id pub-id-type="pmcid-ver">PMC12407133.1</article-id><article-id pub-id-type="pmcaid">12407133</article-id><article-id pub-id-type="pmcaiid">12407133</article-id><article-id pub-id-type="pmid">40875513</article-id><article-id pub-id-type="doi">10.34067/KID.0000000810</article-id><article-id pub-id-type="publisher-id">K360-2025-000349</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>To Hold or Not to Hold, that is the Newest Sodium-Glucose Cotransporter-2 Inhibitor Question</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0056-4530</contrib-id><name name-style="western"><surname>Murphy</surname><given-names initials="DP">Daniel P.</given-names></name><role vocab="CRediT" vocab-identifier="http://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="http://credit.niso.org/contributor-roles/conceptualization/"/><role vocab="CRediT" vocab-identifier="http://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-original-draft/"/><role vocab="CRediT" vocab-identifier="http://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="http://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><aff>Department of Medicine, University of Minnesota, Minneapolis, Minnesota</aff></contrib-group><author-notes><corresp><bold>Correspondence:</bold> Dr. Daniel P. Murphy, email: <email>murph670@umn.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>8</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>28</day><month>8</month><year>2025</year></pub-date><volume>6</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">496170</issue-id><fpage>1254</fpage><lpage>1255</lpage><pub-history><event event-type="pmc-release"><date><day>28</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Nephrology</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND)</ext-link>, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="kidney360-6-1254.pdf"/><self-uri xlink:href="kidney360-6-1254.pdf"/><related-article related-article-type="companion" xml:lang="en" xlink:title="research-article" journal-id="Kidney360" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC12407127"><article-title>Sodium-Glucose Cotransporter 2 Inhibitors in Patients Undergoing Coronary Angiography</article-title><volume>6</volume><issue>8</issue><date><day>21</day><month>3</month><year>2025</year></date><fpage>1317</fpage><lpage>1327</lpage><source>Kidney360</source><pub-id pub-id-type="doi">10.34067/KID.0000000781</pub-id><pub-id pub-id-type="pmcid">PMC12407127</pub-id><pub-id pub-id-type="pmid">40116863</pub-id></related-article><kwd-group><kwd>AKI</kwd><kwd>coronary artery disease</kwd><kwd>SGLT2</kwd></kwd-group><counts><fig-count count="0"/><table-count count="0"/><ref-count count="10"/><page-count count="2"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>Read-along</meta-name><meta-value>YES</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Sodium-glucose cotransporter-2 (SGLT2) inhibitors are becoming increasingly prevalent in their use because of greater uptake<sup><xref rid="B1" ref-type="bibr">1</xref></sup> and a growing list of indications and patient eligibility.<sup><xref rid="B2" ref-type="bibr">2</xref><xref rid="B3" ref-type="bibr"/>&#8211;<xref rid="B4" ref-type="bibr">4</xref></sup> This growing use of SGLT2 inhibitors bring to the fore the issue of how to manage a SGLT2 inhibitor around times of predictable AKI risk. Although SGLT2 inhibitors have demonstrated a familiar hemodynamic decrease in kidney function,<sup><xref rid="B3" ref-type="bibr">3</xref></sup> they have been shown to decreased the risk for AKI overall.<sup><xref rid="B5" ref-type="bibr">5</xref></sup> Despite this reassuring finding, it remains plausible that certain clinical situations call for a reversal of this hemodynamic decrease in kidney function.</p><p>For patients undergoing nonemergent coronary angiography, their AKI risk is certainly able to be anticipated and mitigation efforts enacted. Interventions such as minimizing contrast load<sup><xref rid="B6" ref-type="bibr">6</xref></sup> or administration of prophylactic intravenous fluids have been shown to be helpful in reducing AKI risk.<sup><xref rid="B7" ref-type="bibr">7</xref></sup> Just as questions of holding or continuing renin-angiotensin-aldosterone system (RAAS) inhibitors have previously arisen (and the balance of risks and benefits remains an open question),<sup><xref rid="B8" ref-type="bibr">8</xref></sup> the question of whether to hold or not to hold a patient's SGLT2 inhibitor now faces clinicians counseling patients before a coronary angiography.</p><p>This background frames the multicenter randomized clinical trial conducted by Phatikraisri <italic toggle="yes">et al.</italic> which protocolized withholding or continuing patients' SGLT2 inhibitors for 72 hours before coronary angiography and resuming the medication, if held, the morning after angiography or as soon as clinically appropriate.<sup><xref rid="B9" ref-type="bibr">9</xref></sup> Their study team used significant resources to ensure and confirm participants' adherence to their treatment assignments. Providers performing the angiography were the sole group who were blinded. The 200 participants, 82% of whom had diabetes mellitus, 39% of whom had chronic heart failure, and 32.5% of whom had moderate to advanced CKD, were then assessed for AKI through a standardized definition for AKI, serving as the primary outcome for the study. Postprocedure and 90-day renal and cardiovascular outcomes were also assessed. Finally, safety outcomes were captured, including the occurrence of ketoacidosis and decompensation of heart failure.</p><p>It is worth noting that nearly all trial participants received intravenous fluids before their angiography, and while only four in ten participants were concomitantly using RAAS inhibitors, RAAS inhibitors were held shortly before the procedure and resumed immediately afterward across the arms of the study. Just under half of the participants required percutaneous coronary intervention alongside their diagnostic angiography, and a femoral approach for the procedure predominated. Perhaps most importantly, the contrast volumes used were largely kept low.<sup><xref rid="B6" ref-type="bibr">6</xref></sup> Under these conditions, the authors of this study observed an unexpected low frequency of AKI across the study arms as compared with their prestudy assumptions. They found AKI in 3.9% (or four cases) of participants who continued their SGLT2 inhibitor and 3.1% (three cases) in those who had theirs held. Populations not well matching these baseline, preprocedural, and/or procedural factors may find that these trial results do not extrapolate to themselves.</p><p>With the unexpected low rates of AKI in both arms of their study, this study was not able to detect with statistical confidence that holding SGLT2 inhibitors had an effect on AKI risk (<italic toggle="yes">P</italic> = 0.74). Small and not clinically meaningful differences between the arms of the study in serum creatinine changes preprocedure to postprocedure (but not the corresponding eGFR changes) were appreciated in the postprocedure secondary outcomes. Ninety-day and safety outcomes did not show statistical differences (or, with one case of ketoacidosis, it could not be statistically compared to zero cases). These low rates of AKI across arms of the trial may reflect the predictably low-risk nature of the patient population studied and the low-risk nature of this procedure when conducted electively. The authors recognized this, reporting that fewer than one in five of their participants had a particularly elevated AKI risk score (which includes in the scoring equation the contrast volume given in addition to baseline and preprocedure factors).<sup><xref rid="B10" ref-type="bibr">10</xref></sup> The authors also postulate that their patients may have enjoyed renoprotective effects from SGLT2 inhibitor use regardless of whether the medication was held or not before the procedure.</p><p>Although it is impossible to say statistically in this trial whether withholding SGLT2 inhibitors affected (either favorably or unfavorably) an already low risk for contrast-associated AKI, it is <italic toggle="yes">clear</italic> clinically that neither withholding nor continuing patients' SGLT2 inhibitors for coronary angiography caused significant rates of harm when the patients and the circumstances were low-risk for AKI. It is also <italic toggle="yes">unclear</italic>, if risk of contrast-associated AKI actually could be further decreased in low-risk patients treated with a procedure done in a low-risk manner, whether withholding a medication without a protocol to ensure resumption would justify the risks that some patients may not resume their medication. Thus, the authors appropriately conclude: &#8220;These findings suggest that routine discontinuation of SGLT2 inhibitors before elective coronary angiography may not be necessary in this population.&#8221; Of course, further study of the optimal management of SGLT2 inhibitors, particularly in patients at high risk for contrast-associated AKI and/or when low to modest contrast volumes are unlikely, is needed.</p><sec sec-type="supplementary-material"><title>Supplementary Material</title><fig id="s001" position="anchor" orientation="portrait"><media xlink:href="kidney360-6-1254-s001.pdf" position="float" orientation="portrait"/></fig></sec></body><back><ack><title>Acknowledgments</title><p>The content of this article reflects the personal experience and views of the author and should not be considered medical advice or recommendation. The content does not reflect the views or opinions of the American Society of Nephrology (ASN) or <italic toggle="yes">Kidney360</italic>. Responsibility for the information and views expressed herein lies entirely with the author.</p></ack><fn-group><fn fn-type="other"><p>See related article, &#8220;Sodium-Glucose Cotransporter 2 Inhibitors in Patients Undergoing Coronary Angiography: A Randomized Controlled Trial (BELIEVE Trial),&#8221; on pages 1317&#8211;1327.</p></fn></fn-group><sec sec-type="COI-statement"><title>Disclosures</title><p>Disclosure forms, as provided by each author, are available with the online version of the article at <ext-link xlink:href="http://links.lww.com/KN9/B30" ext-link-type="uri">http://links.lww.com/KN9/B30</ext-link>.</p></sec><sec sec-type="funding"><title>Funding</title><p>None.</p></sec><sec sec-type="author-contributions"><title>Author Contributions</title><p><bold>Conceptualization:</bold> Daniel P. Murphy.</p><p><bold>Writing &#8211; original draft:</bold> Daniel P. Murphy.</p><p><bold>Writing &#8211; review &amp; editing:</bold> Daniel P. Murphy.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozaki</surname><given-names>AF</given-names></name><name name-style="western"><surname>Ko</surname><given-names>DT</given-names></name><name name-style="western"><surname>Chong</surname><given-names>A</given-names></name>, <etal/></person-group>. <article-title>Prescribing patterns and factors associated with sodium-glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease</article-title>. <source>CMAJ Open.</source><year>2023</year>;<volume>11</volume>(<issue>3</issue>):<fpage>E494</fpage>&#8211;<lpage>E503</lpage>. doi:<pub-id pub-id-type="doi">10.9778/cmajo.20220039</pub-id><pub-id pub-id-type="pmcid">PMC10270657</pub-id><pub-id pub-id-type="pmid">37311594</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><collab>American Diabetes Association Professional Practice Committee</collab>. <article-title>11. Chronic kidney disease and risk management: standards of care in diabetes-2024</article-title>. <source>Diabetes Care.</source><year>2024</year>;<volume>47</volume>(<issue>suppl 1</issue>):<fpage>S219</fpage>&#8211;<lpage>S230</lpage>. doi:<pub-id pub-id-type="doi">10.2337/dc24-S011</pub-id><pub-id pub-id-type="pmid">38078574</pub-id><pub-id pub-id-type="pmcid">PMC10725805</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heerspink</surname><given-names>HJL</given-names></name><name name-style="western"><surname>Stefansson</surname><given-names>BV</given-names></name><name name-style="western"><surname>Correa-Rotter</surname><given-names>R</given-names></name>, <etal/></person-group>. <article-title>Investigators: dapagliflozin in patients with chronic kidney disease</article-title>. <source>N Engl J Med.</source><year>2020</year>;<volume>383</volume>(<issue>15</issue>):<fpage>1436</fpage>&#8211;<lpage>1446</lpage>. doi:<pub-id pub-id-type="doi">10.1056/nejmoa2024816</pub-id><pub-id pub-id-type="pmid">32970396</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Talha</surname><given-names>KM</given-names></name><name name-style="western"><surname>Anker</surname><given-names>SD</given-names></name><name name-style="western"><surname>Butler</surname><given-names>J</given-names></name></person-group>. <article-title>SGLT-2 inhibitors in heart failure: a review of current evidence</article-title>. <source>Int J Heart Fail.</source><year>2023</year>;<volume>5</volume>(<issue>2</issue>):<fpage>82</fpage>&#8211;<lpage>90</lpage>. doi:<pub-id pub-id-type="doi">10.36628/ijhf.2022.0030</pub-id><pub-id pub-id-type="pmid">37180562</pub-id><pub-id pub-id-type="pmcid">PMC10172076</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><collab>Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium</collab>. <article-title>Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials</article-title>. <source>Lancet.</source><year>2022</year>;<volume>400</volume>(<issue>10365</issue>):<fpage>1788</fpage>&#8211;<lpage>1801</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(22)02074-8</pub-id><pub-id pub-id-type="pmid">36351458</pub-id><pub-id pub-id-type="pmcid">PMC7613836</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>James</surname><given-names>MT</given-names></name><name name-style="western"><surname>Har</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Tyrrell</surname><given-names>BD</given-names></name>, <etal/></person-group>. <article-title>Effect of clinical decision support with audit and feedback on prevention of acute kidney injury in patients undergoing coronary angiography: a randomized clinical trial</article-title>. <source>JAMA.</source><year>2022</year>;<volume>328</volume>(<issue>9</issue>):<fpage>839</fpage>&#8211;<lpage>849</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2022.13382</pub-id><pub-id pub-id-type="pmid">36066520</pub-id><pub-id pub-id-type="pmcid">PMC9449791</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jurado-Rom&#225;n</surname><given-names>A</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Hern&#225;ndez</surname><given-names>F</given-names></name><name name-style="western"><surname>Garc&#237;a-Tejada</surname><given-names>J</given-names></name>, <etal/></person-group>. <article-title>Role of hydration in contrast-induced nephropathy in patients who underwent primary percutaneous coronary intervention</article-title>. <source>Am J Cardiol.</source><year>2015</year>;<volume>115</volume>(<issue>9</issue>):<fpage>1174</fpage>&#8211;<lpage>1178</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.amjcard.2015.02.004</pub-id><pub-id pub-id-type="pmid">25759106</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#246;lscher</surname><given-names>B</given-names></name><name name-style="western"><surname>Heitmeyer</surname><given-names>C</given-names></name><name name-style="western"><surname>Fobker</surname><given-names>M</given-names></name><name name-style="western"><surname>Breithardt</surname><given-names>G</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>RM</given-names></name><name name-style="western"><surname>Reinecke</surname><given-names>H</given-names></name></person-group>. <article-title>Predictors for contrast media-induced nephropathy and long-term survival: prospectively assessed data from the randomized controlled Dialysis-Versus-Diuresis (DVD) trial</article-title>. <source>Can J Cardiol.</source><year>2008</year>;<volume>24</volume>(<issue>11</issue>):<fpage>845</fpage>&#8211;<lpage>850</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0828-282x(08)70193-4</pub-id><pub-id pub-id-type="pmid">18987758</pub-id><pub-id pub-id-type="pmcid">PMC2644537</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phatikraisri</surname><given-names>T</given-names></name><name name-style="western"><surname>Krisem</surname><given-names>M</given-names></name><name name-style="western"><surname>Chantadansuwan</surname><given-names>T</given-names></name>, <etal/></person-group>. <article-title>Sodium-glucose cotransporter 2 inhibitors in patients undergoing coronary angiography: a randomized controlled trial (BELIEVE trial)</article-title>. <source>Kidney360.</source><year>2025</year>;<volume>6</volume>(<issue>8</issue>):<fpage>1317</fpage>&#8211;<lpage>1327</lpage>. doi:<pub-id pub-id-type="doi">10.34067/KID.0000000781</pub-id><pub-id pub-id-type="pmid">40116863</pub-id><pub-id pub-id-type="pmcid">PMC12407127</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehran</surname><given-names>R</given-names></name><name name-style="western"><surname>Aymong</surname><given-names>ED</given-names></name><name name-style="western"><surname>Nikolsky</surname><given-names>E</given-names></name>, <etal/></person-group>. <article-title>A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation</article-title>. <source>J Am Coll Cardiol.</source><year>2004</year>;<volume>44</volume>(<issue>7</issue>):<fpage>1393</fpage>&#8211;<lpage>1399</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jacc.2004.06.068</pub-id><pub-id pub-id-type="pmid">15464318</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>